Transforming vaccines with breakthrough VLP technology

Corporate profile

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes clinical and preclinical programs targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and flu. Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

Press releases

January 6, 2023
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
December 13, 2022
Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint
November 22, 2022
Icosavax to Participate in the Evercore ISI HealthCONx Conference

Events

December 1, 2022 at 3:55 PM EST
5th Annual Evercore ISI HealthCONx Conference
November 17, 2022 at 6:20 AM EST
Jefferies London Healthcare Conference
November 15, 2022 at 9:00 AM EST
Guggenheim 4th Annual Immunology and Neurology Conference

Latest presentation

January 2023
Corporate Overview
Investor Email Alerts